David S. Celermajer

David S. Celermajer

MBBS, MSc, PhD, DSc, FAHA, FRACP, FAA, FAAHMS

Cardiologist

Over 40 years of experience

Male📍 Camperdown

About of David S. Celermajer

David S. Celermajer is a cardiologist based in Camperdown, NSW. He works from 50 Missenden Rd, where he helps people with a wide range of heart and blood vessel conditions, from birth problems to issues that develop later in life. If you’re not sure where your symptoms fit, he can still be a useful starting point to work out what’s going on.


He has over 40 years of experience. That means he’s seen many different heart problems and how they can change over time. In many cases, people come in with high blood pressure, valve problems, heart rhythm issues, or heart failure. He also looks after congenital heart disease, which covers heart conditions that are present from birth.


David’s training includes a strong focus on children’s heart conditions. He completed a PhD in Children’s Heart Disease, along with earlier study at the University of Sydney and further degrees at the University of Oxford and the University of London. He also holds MBBS and higher qualifications, including FRACP, and fellowships with relevant Australian and international cardiology bodies.


Over the years, his work has included care for conditions like pulmonary hypertension, coarctation of the aorta, and several types of congenital heart disease. He also treats people with problems such as aortic valve stenosis and aortic regurgitation, atrial fibrillation, and other heart rhythm issues. When it comes to coronary heart disease and heart attacks, he focuses on the long-term plan, not just the day of treatment.


Some patients need ongoing support for heart failure. Others may be dealing with things that raise their heart risk over time, such as high cholesterol, obesity and metabolic syndrome, and type 2 diabetes. There are also times when heart issues show up alongside other health problems, and that’s where clear coordination and steady follow-up really matter.


In terms of research, his education includes advanced study and research qualifications, including a Doctor of Philosophy and a Doctor of Science. This background helps him understand heart disease in a deeper way, but he keeps the conversation practical. The goal is to explain what’s happening, what tests might help, and what treatment options make sense for each person’s situation.


For clinical trials, specific trial involvement isn’t listed here. Still, his long career and research training mean he stays up to date with changes in cardiology care as new evidence comes through.

Education

  • Bachelor of Medicine, Bachelor of Surgery (MBBS); University of Sydney; 1982
  • MSc, Medicine - Rhodes Scholarship ; University of Oxford; 1985
  • Bachelor of Arts (BA) in Philosophy, Politics, and Economics (PPE); University of Oxford; 1985
  • Doctor of Philosophy (PhD) in Children's Heart Disease; University of London; 1993
  • Doctor of Science (D.Sc.); University of Sydney

Services & Conditions Treated

Coarctation of the AortaCongenital Heart Disease (CHD)Pulmonary HypertensionDouble Inlet Left VentricleHypertensionTetralogy of FallotTricuspid AtresiaAortic RegurgitationAtherosclerosisAtrial Septal Defect (ASD)Bicuspid Aortic ValveCardiac ArrestCardiomyopathyCerebral HypoxiaCongenital Cardiovascular ShuntCor PulmonaleCoronary Heart DiseaseDouble DiscordiaEisenmenger SyndromeEndocardial FibroelastosisEndocarditisHeart FailureHeterotaxy SyndromeHigh Blood Pressure in InfantsHypertensive Heart DiseaseHypoplastic Left Heart Syndrome (HLHS)Patent Foramen OvaleRheumatic FeverStrep ThroatTransposition of the Great ArteriesTricuspid RegurgitationVentricular FibrillationAbdominal Obesity Metabolic SyndromeAcute Coronary SyndromeAortic DissectionAortic Valve StenosisArrhythmiasArthritisAsthma in ChildrenAtrial FibrillationAtrioventricular Nodal Reentrant Tachycardia (AVNRT)BronchitisCardiac TamponadeCarotid Artery DiseaseCoronary Artery SpasmDextrocardiaDextrocardia with Situs InversusDilated Cardiomyopathy (DCM)Ebstein's AnomalyEndomyocardial FibrosisErectile Dysfunction (ED)Heart AttackHeart Failure with Preserved Ejection Fraction (HFpEF)Heart TransplantHigh CholesterolHolt-Oram SyndromeImpetigoInfective EndocarditisMalnutritionMetabolic SyndromeMitral StenosisMitral Valve RegurgitationMyotonic DystrophyMyotonic Dystrophy Type 2ObesityObstructive Sleep ApneaParamyotonia CongenitaPeriodontitisPleural EffusionPulmonary AtresiaPulmonary Atresia with Intact Ventricular SeptumPulmonary EmbolismPulmonary Valve StenosisSclerodermaSepsisSitus InversusStrokeSystemic Sclerosis (SSc)Thoracic Aortic AneurysmThrombectomyType 2 Diabetes (T2D)VasoconstrictionVentricular Septal DefectsVitamin B12 Deficiency AnemiaWildervanck Syndrome

Publications

5 total
Characteristics of pulmonary hypertension in adults with left ventricular diastolic dysfunction.

Open heart • January 09, 2025

Seshika Ratwatte, Simon Stewart, David Playford, Geoff Strange, David Celermajer

Objective: Left ventricular diastolic dysfunction (LVDD) is commonly associated with pulmonary hypertension (PHT); however, the factors associated with the presence and severity of PHT in patients with LVDD have not been well characterised. Methods: We analysed the profiles and echo characteristics of 16 058 adults with LVDD and preserved left ventricular ejection fraction (LVEF, >50%) from the National Echocardiography Database of Australia. Peak tricuspid regurgitation velocity (TRV) was used to determine the presence of PHT. Univariate and multivariate analyses were performed to evaluate the parameters associated with the presence/increasing severity of PHT. Results: Mean age was 73±12 years and 9216 (57.4%) were women. 2503 (15.6%) subjects had atrial fibrillation (AF) and 13 555 (84.4%) were in sinus rhythm. Overall, 9976 (62.1%) had PHT (TRV >2.9 m/s). There was a progressive increase in indexed left atrial volume with rising TRV levels. AF and right ventricular (RV) dilation were strongly associated with the presence of PHT (adjusted OR (aOR) 1.27 (95% CI 1.12 to 1.43) and aOR 4.99 (95% CI 4.44 to 5.62), respectively). Increased age, LVEF and body mass index were also independently associated with PHT (p<0.001). On multivariate analysis, older age, female sex, AF, lower E/e' and LVEF were independently associated with the severity of PHT (p<0.001). The presence of AF increased the TRV by an average of 0.32 m/s, RV dilation by 1.82 m/s, female sex by 0.32 m/s and age (per decade) by 0.3 m/s. Conclusions: In this large study, PHT was common in LVDD and was strongly associated with the presence of enlarged left atrium, AF and older age, in particular.

Evaluating the Role of Lipoprotein(a) in Enhancing Risk Stratification for the Presence and Extent of Subclinical Coronary Artery Disease Burden - A BioHEART-CT Study.

European Journal Of Preventive Cardiology • February 07, 2025

Sina Fathieh, Owen Tang, Michael Gray, Christian Zanchin, Stephen Vernon, Elijah Genetzakis, Collin Tran, David Sullivan, Stephen Nicholls, David Celermajer, Peter Psaltis, Stuart Grieve, Gemma Figtree

Objective: Lipoprotein(a) [Lp(a)] has regained attention as an independent cardiovascular risk factor, particularly given emerging therapies entering late-phase clinical trials. Here, we aim to examine the association of Lp(a) with CAD and the potential of Lp(a) as an enrichment criterion for identifying individuals more likely to benefit from screening for subclinical CAD with CT imaging. Methods: We analysed data from 1,718 adults undergoing CTCA for suspected CAD enrolled in the BioHEART study. Lp(a) levels were measured, and CAD burden was assessed using coronary artery calcium score (CACS) and Gensini scores. Plaque morphology for the most stenotic plaque of each Gensini segment was classified as calcified, non-calcified or mixed. Youden's index with 10,000 bootstraps was used to identify the optimal threshold for increased risk of clinically actionable CAD. Results: Lp(a) was strongly associated with all CTCA measures of CAD examined. Elevated Lp(a) above 22 nmol/L was linked to more advanced multi-segment (ordinal OR = 1.14 [1.03-1.25]) and multivessel disease (ordinal OR = 1.11 [1.02-1.20]), with a 2.6% increased risk of a CACS >100 for every 10 nmol/L increment. Lp(a) was most strongly associated with mixed plaque burden even after adjusting for traditional risk factors (β = 4.75, p=0.001), but not with non-calcified or calcified plaque. Adding Lp(a) to standard risk models resulted in an overall NRI of 16% [0.06-0.27] and 42% [0.16-0.70] in patients without standard modifiable risk factors. Conclusions: Our findings suggest Lp(a)'s role in a new clinical pathway: screening patients considered low or intermediate risk, particularly those without standard modifiable risk factors for non-invasive imaging to detect subclinicalCAD.

Excellent medium to long term outcomes after cardiac surgery for moderate and complex congenital heart disease, regardless of geographic location.

International Journal Of Cardiology. Congenital Heart Disease • February 17, 2025

Larissa Lloyd, Calum Nicholson, Geoff Strange, Rachael Cordina, David Celermajer, Michael M Cheung

To compare the outcomes for repaired tetralogy of Fallot and Fontan patients who must travel from regional Victoria and interstate, in order to receive specialist congenital heart disease (CHD) surgery and ongoing care, with those of local patients. This retrospective study included 332 patients who underwent tetralogy of Fallot (ToF) repair and 159 patients who underwent a Fontan procedure at Royal Children's Hospital (RCH) Melbourne between 2003 and 2017. Data was obtained from the National CHD Registry, linked with National Death Index data, and follow-up data from the Australian and New Zealand Fontan Registry. Equivalent outcomes were observed between location groups in both cohorts for all of the main outcomes of interest. Repaired ToF subjects were aged 0.76 years (IQR 0.52-3.33) at operation and 10.2 years (IQR 5.46-14.9) at last follow-up, whilst Fontan subjects were aged 4.94 (IQR 4.27-5.66) years at operation and 14.2 years (IQR 11.3-16.4) at last follow-up. Mortality rates were extremely low and did not significantly differ between geographic groups, with 10-year survival in the repaired ToF cohort 98.0 % in the City group, 98.1 % in the Regional group, and 98.8 % in the Interstate group; and 97.8 %, 92.3 %, and 97.5 % in the Fontan cohort, respectively. In the Australian setting and with adequate planning and local follow-up options, patients travelling from regional areas or interstate for their CHD operations have similar outcomes, out to 21 years, compared to patients living locally.

Wellbeing and quality of life among parents of individuals with Fontan physiology.

Quality Of Life Research : An International Journal Of Quality Of Life Aspects Of Treatment, Care And Rehabilitation • January 03, 2025

Kate Marshall, Yves D'udekem, David Winlaw, Diana Zannino, David Celermajer, Karen Eagleson, Ajay Iyengar, Dominica Zentner, Rachael Cordina, Gary Sholler, Susan Woolfenden, Nadine Kasparian

Objective: To examine global and health-related quality of life (QOL) among parents of individuals with Fontan physiology and determine associations with sociodemographic, parent and child-related health, psychological, and relational factors. Methods: Parents participating in the Australian and New Zealand Fontan Registry (ANZFR) QOL Study (N = 151, Parent Mean age = 47.9 ± 10.2 years, age range: 31.6-79.6 years, 66% women; child Mean age = 16.3 ± 8.8, age range: 6.9-48.7 years, 40% female) completed a series of validated measures. Health-related QOL was assessed using the PedsQL 4.0 Core Generic Scales for adults and global QOL was assessed using a visual analogue scale (0-10). Results: Most parents (81%) reported good global QOL (≥ 6), consistent with broader population trends. Nearly one-third of parents (28%) reported at-risk health-related QOL (based on total PedsQL scores) with physical functioning most affected (44%). Psychological factors, including psychological stress and sense of coherence, emerged as the strongest correlates of global and health-related QOL, explaining an additional 16 to 30% of the variance (using marginal R2). Final models explained 35 and 57% and of the variance in global and health-related QOL, respectively (marginal R2). Relational factors, including perceived social support and family functioning contributed minimally when analyzed alongside psychological variables. Conclusions: While parents of individuals with Fontan physiology report good global QOL, challenges in health-related QOL exist. We identified key psychological, sociodemographic, and health-related factors associated with parental QOL outcomes. These data may aid early identification of physical and psychosocial difficulties and guide targeted health resource allocation for this population.

Rheumatic heart disease 2025 - current status and future challenges.

Australian Health Review : A Publication Of The Australian Hospital Association • December 18, 2024

Benjamin Jones, David Celermajer

Rheumatic heart disease remains a major health problem for Aboriginal and Torres Strait Islander peoples. In this Reflection, potential solutions to this lamentable situation are reviewed.

Frequently Asked Questions

What conditions does Dr David S. Celermajer treat?
Dr Celermajer is a cardiologist who manages a range of heart and blood vessel conditions, including congenital heart disease, hypertension, arrhythmias, heart failure, coronary heart disease, aortic problems, valve issues, and vascular concerns.
What services are offered by Dr Celermajer?
His services cover many heart-related conditions and procedures, such as assessment and management of congenital heart disease, cardiomyopathy, pulmonary hypertension, hypertension, coronary disease, valvular disease, arrhythmias, and related vascular and metabolic issues.
Where is the clinic located?
The practice is at 50 Missenden Rd, Camperdown, NSW 2050, Australia.
How do I book an appointment?
To arrange an appointment, please contact the clinic directly. The exact booking method isn’t provided here, but the address above is where visits are held.
What should I expect at my first visit?
Initial visits typically involve reviewing your medical history, current symptoms, and any test results relevant to heart health, followed by a plan tailored to your condition.
Who is this doctor suitable for?
Dr Celermajer has extensive experience spanning over 40 years and works with patients facing a wide range of heart and vascular conditions, including congenital heart disease and common adult cardiac issues.

Contact Information

50 Missenden Rd, Camperdown, NSW 2050, Australia

Is this your profile?

Claim this profile →

Memberships

  • Australian Academy of Science (FAA)
  • Australian Academy of Health and Medical Sciences (FAHMS)
  • American Heart Association (FAHA)
  • Royal Australasian College of Physicians (FRACP)
  • Congenital Heart Alliance of Australia and New Zealand
  • HeartKids Australia
  • Editorial Boards of Leading Cardiology Journals